At a glance
An experimental approach to targeting the blood supply of adipose tissue.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Animal weight-loss observations are discussed in the source. Their interpretation requires attention to renal toxicity findings and the limitations of translating the experimental approach to humans.[1][2][8]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Adipotide.
Source-reported adverse effects and cautions
Observations from preclinical literature and limited human data.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 250 mcg | 7.5 units (0.08 mL) |
| Weeks 3–4 | 500 mcg | 15 units (0.15 mL) |
| Weeks 5–6 | 750 mcg | 22.5 units (0.23 mL) |
| Weeks 7–8 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) and starts at a conservative dose with gradual escalation to mitigate potential renal side effects observed at higher doses in preclinical studies[1][2]. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Targeted reduction of fat mass via vascular targeting in adipose tissue[2][8].
- Schedule: Daily subcutaneous injections for 4–8 weeks (cautious approach due to limited human data)[3][9].
- Dose Range: 250–1000 mcg daily with gradual titration every 2 weeks.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw[5].
Suggested daily titration approach.
- Start: 250 mcg daily for Weeks 1–2; increase by 250 mcg every 2 weeks as tolerated[3][9].
- Target: Up to 1000 mcg (1.0 mg) daily by Weeks 7–8 (if well‑tolerated).
- Frequency: Once per day (subcutaneous).
- Cycle Length: 4–8 weeks (based on preclinical effective treatment duration; extend with extreme caution).
- Timing: Any consistent time; rotate injection sites systematically.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light[5].
Storage Instructions
Proper storage preserves peptide quality.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[6][7].
- Clean the vial stopper and skin with alcohol; allow to dry fully.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (45° if limited subcutaneous fat, 90° if ample tissue)[6].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation.
- Wait a moment before withdrawing the needle; apply gentle pressure but do not rub the injection site.
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–week cautious titration protocol with once‑daily administration.
-
Peptide Vials (Adipotide, 10 mg each):
- 8 weeks ≈ 4 vials
- 12 weeks ≈ 7 vials
- 16 weeks ≈ 10 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
- 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
- 05
Source document
Bachem Technical Note — Care and Handling of Peptides (opens in a new tab)www.bachem.com
Back to overview ↑ - 08
Source document
Los Angeles Times — Cancer treatment shows promise for rapid weight loss (opens in a new tab)www.latimes.com
Back to overview ↑ - 09
Source document
ScienceDaily — Obese monkeys lose weight on drug that attacks blood supply of fat cells (opens in a new tab)www.sciencedaily.com
Back to overview ↑ - 10
Public health resource
CDC — Vaccine administration: subcutaneous route guidance (opens in a new tab)www.cdc.gov
Back to overview ↑ - 11
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑ - 12
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 13
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.